‘Tiltan Pharma’ Starts Phase II Trial For Pancreatic Cancer Drug

Tiltan Pharma Ltd. announced it has started phase II of its clinical trial for its new drug for pancreatic cancer, following approval by the Israeli Ministry of Health. The drug is designed to prevent blood flow to tumors and prevent their growth. The second phase of the trial will include 80 patients: 40 with newly diagnosed cancer who have not yet been treated with chemotherapy, and 40 as a control group. The control group will be treated with standard chemotherapy for pancreatic cancer and the others will receive the new drug (TL-118) in addition to standard chemotherapy. View and share